We first showed conclusively that CD1d+ tumor/Gal in hematological malignancy models, including a lymphoma (EL4), leukemia (WEHI3B), and plasmacytoma (J558) model, can induce antigen-specific CD4+ and CD8+ T cell immunity [154,155]. Here, GAL is linked to neoplasm.